Generics and Biosimilars: Ensuring Quality from Beginning to End

By PerkinElmer

When a new drug is first developed by a pharmaceutical company, it is initially sold under a brand name and the product is covered under patent protection. This means that the only company allowed to manufacture, market, and profit from the drug is the innovator company that holds the patent.

However, once a patent expires, opportunities arise for companies other than the innovator to manufacture and sell the product as a generic or biosimilar medicine.

To read more, please download this free white paper.

Enter your details below to view the free white paper

By downloading this whitepaper, you acknowledge that GlobalData may share your information with our white paper partners/sponsors who may contact you directly with information on their products and services.

Visit our Privacy Policy for more information about our services, how GlobalData may use, process and share your personal data, including information on your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.